BullFrog AI Holdings, Inc.

BullFrog AI Holdings, Inc. announced an increase in CEO Vininder Singh's annual base salary from $400,000 to $600,000, effective June 11, 2026. His target annual bonus was also adjusted to a maximum of 50% of his current base salary. Additionally, the company held its 2026 Annual Meeting of Stockholders where four director nominees were elected and the appointment of M&K CPAs, PLLC as the independent registered public accounting firm for 2026 was ratified.

BullFrog AI Holdings, Inc. filed an S-1 registration statement for the resale of up to 2,000,000 shares of common stock by Lincoln Park Capital Fund, LLC. These shares are part of an existing Purchase Agreement, under which BullFrog AI may receive up to an additional $4,099,102 from future sales. The company recently regained compliance with Nasdaq's stockholders' equity requirement but faces a potential delisting due to its stock price falling below $1.00. Additionally, BullFrog AI entered a feasibility agreement with a global pharmaceutical company for drug target discovery using its bfLEAP® AI/ML platform.

BullFrog AI Holdings reported a narrowed net loss of $1.59 million for the first quarter of 2026, an improvement from $2.02 million in the prior year. The company significantly increased its cash and cash equivalents to $5.08 million and total stockholders' equity to $4.89 million, primarily driven by $4.59 million in net cash from financing activities. This capital raise enabled the company to regain compliance with Nasdaq's Stockholders' Equity Rule on April 21, 2026, though it remains subject to a one-year monitoring period. However, BullFrog AI also received a Nasdaq notice in February 2026 regarding non-compliance with the minimum $1.00 bid price requirement, for which it has until August 10, 2026, to regain compliance.

BullFrog AI Holdings, Inc. announced its Virtual Annual Meeting of Stockholders to be held on June 11, 2026. Stockholders of record as of April 20, 2026, will vote on the election of four directors and the ratification of M&K CPAs, PLLC as the independent registered public accounting firm for fiscal year 2026. The company is utilizing the "Notice and Access" method for proxy materials. The Board of Directors unanimously recommends voting "FOR" all proposals.

BullFrog AI Holdings, Inc. announced that it has regained compliance with Nasdaq's minimum stockholders' equity requirement. The company received a notification letter from the Nasdaq Stock Market on April 21, 2026, confirming its compliance with Listing Rule 5550(b)(1). This development removes a potential delisting concern for the company.

BullFrog AI Holdings, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000 as of April 21, 2026. The company achieved this through sales under its at-the-market and equity-line-of-credit facilities. While compliant, BullFrog AI will be subject to a one-year mandatory panel monitor, with no additional time to regain compliance if it falls short again during this period. CEO Vin Singh highlighted a recent commercial agreement and extended cash runway as key factors.

BullFrog AI Holdings, Inc. announced that its 2026 Annual Meeting of Stockholders will take place on June 11, 2026. Due to this meeting date being more than 30 days before the anniversary of the 2025 annual meeting, the deadlines for shareholder proposals and nominations have been updated. Shareholder proposals and nominations are now required to be submitted by April 29, 2026, and must adhere to all applicable regulatory and company bylaw requirements.

BullFrog AI Holdings, Inc. provided a business update, announcing a strengthened balance sheet and securing its financial runway into late 2027. The company has entered its first commercial agreement with a top 5 global pharmaceutical company, signaling a significant step in its commercialization strategy. BullFrog AI is actively engaged in discussions with other pharmaceutical and biotechnology organizations to further ramp up its commercial activities.

BullFrog AI Holdings announced a commercial feasibility agreement with a top 5 global pharmaceutical company to identify novel drug targets in major depressive disorder using its bfLEAP platform. This agreement includes milestone payments and an option for exclusive rights to a selected target. The company also secured financial runway into late 2027 and launched bfARENAS", completing its integrated AI platform for pharmaceutical R&D.